Investor Presentation • Apr 20, 2017
Investor Presentation
Open in ViewerOpens in native device viewer
April 20, 2017
Forward-looking statements involve risks.
This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this.
This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected.
It is not planned to update these forward-looking statements.
(1) figure adjusted for one-off items resulting from transaction activities and related reorganization expenses
(2) figure additionally adjusted for financing expenses and tax expenses in connection with the acquisitions of the Diatron Group and STRATEC Consumables, for one-off items resulting from the tax audit for the 2009 to 2013 assessment periods, and for tax effects relating to reorganization expenses
Implementation of a group-wide ERP system
2016 at a Glance
• 2016: +25.9% to € 184.9 million
Annual Sales as of 12/31
Installed Base and Product Groups
As of December 31
Delivered systems & installed base Relative share by product group
Service parts
Number of analyzer systems delivered
* 2016 includes delivered systems by Diatron
FY 2016 Annual Results Conference Call – April 20, 2017
EBIT margin at 17.5%* (2015: 18.3%)
| € 000s | $01.01 - 12.31.2016$ |
|---|---|
| Adjusted EBIT | 32,273 |
| Adjustments | |
| Expenses due to company acquisitions | $-1,199$ |
| Internal integration expenses | -389 --------------------------------------- |
| Recognition of hidden reserves in inventories less reversal of an onerous contract |
$-823$ |
| PPA amortization | $-4,807$ |
| Reorganization expenses | $-851$ |
| EBIT | 24,204 |
FY 2016 Annual Results Conference Call – April 20, 2017
*2016 figure adjusted to exclude non-recurring items for transaction activities and adjusted to exclude financing expenses and tax expenses in connection with the acquisition of the Diatron Group and non-recurring items arising from the external tax audit for the assessment periods from 2009 to 2013.
FY 2016 Annual Results Conference Call – April 20, 2017 12
www.stratec.com
| IFRS (€ million) |
2016 | 2015 |
|---|---|---|
| Cash flow – operating activities |
16.3 | 26.0 |
| Cash flow – investment activities |
-86.7 | -8.7 |
| Cash flow – financing activities |
40.6 | -8.7 |
| Free cash flow | -70.4 | 17.3 |
| Cash and cash equivalents at end of period |
26.5 | 56.4 |
FY 2016 Annual Results Conference Call – April 20, 2017 www.stratec.com 16
STRATEC Biomedical AG Gewerbestr. 37 75217 Birkenfeld Germany Tel: +49 7082 7916-0 Fax: +49 7082 7916-999 www.stratec.com
Marcus Wolfinger CEO [email protected]
| TICKER | |
|---|---|
| Symbol: | SBS.DE |
| Bloomberg: | SBS:GR |
| Reuters: | SBSG.DE |
| ISIN: | DE000STRA555 |
| WKN: | STRA55 |
THANK YOU FOR YOUR ATTENTION!
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.